about
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceEZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumorsExpression levels of the ABCG2 multidrug transporter in human erythrocytes correspond to pharmacologically relevant genetic variationsSynthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.Lost in Translation: Regulation of ABCG2 Expression in Human Embryonic Stem CellsBone marrow mesenchymal stem cells provide an antibiotic-protective niche for persistent viable Mycobacterium tuberculosis that survive antibiotic treatmentToxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I studyCollateral sensitivity as a strategy against cancer multidrug resistance.Using the BacMam Baculovirus System to Study Expression and Function of Recombinant Efflux Drug Transporters in Polarized Epithelial Cell MonolayersThe role of transporters in the toxicity of nucleoside and nucleotide analogs.ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan.Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.Species differences in drug transporters and implications for translating preclinical findings to humans.ABCG2: recent discovery of potent and highly selective inhibitors.Hormonal regulation of hepatic drug biotransformation and transport systems.Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivoMasitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.ABCG2/BCRP: Specific and Nonspecific Modulators.Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.Structure of the human multidrug transporter ABCG2.Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.Mitochondrial heme: an exit strategy at last.Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP).Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates.Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.A new fluorescent dye accumulation assay for parallel measurements of the ABCG2, ABCB1 and ABCC1 multidrug transporter functions.Expression and function of ABCG2 and XIAP in glioblastomas.TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.Clinically relevant mutations in the ABCG2 transporter uncovered by genetic analysis linked to erythrocyte membrane protein expression.
P2860
Q26865927-80EA520C-34E7-47D9-BF81-62D6D7EBC798Q27318449-4EDE1344-B418-484F-A8C1-B0624BACB961Q28485221-8C9F9A29-B55C-434B-ADE3-94210D83E0D2Q33773079-F9B4B838-1090-4F9B-AC72-A09C624E98E2Q34508935-A6B51A30-4BC1-42C2-B23E-FC93C670A0C3Q34664183-04B7E8B6-73EB-408C-8EFC-7B75A474B93DQ35687796-D4BB1280-17D6-4CF7-823D-533EFE1F66C6Q35946556-4B219D90-DE03-4767-9335-B1572E1A3939Q36502923-BA53C49C-F791-4389-811E-6D5B879F14E1Q36921993-5309B767-7286-4709-90F9-6FC12F2F722EQ37287637-624C7405-A492-4696-845B-39FFC699C5DEQ37636632-9D8DE278-1928-41E7-8B44-6734F1C82288Q38068912-3777E92D-C77E-425E-A659-43FCCA5EDDD7Q38111799-687BD40B-825D-4EAB-9824-DCB3D3E28C58Q38165145-BAF10556-7DE5-4D78-8D1C-0324B234074AQ38187646-F4E20322-6296-403F-BEE3-01C15F5C7A99Q38207943-985CE43B-ED81-4C62-B4FD-42EF4A020BF2Q38710502-D477F0C9-CED3-4153-8A3E-80161D533508Q39015818-51CF87C2-A814-4DA0-81E7-0EE4322ED53BQ39049159-CB488BFA-266B-4BD7-B603-B1A636960B55Q40926668-A0DAA89E-746A-4B3C-93A2-3F4E1E212AE0Q41597764-B0E5D375-9A61-4D9D-9378-D84EF7ECDD1EQ41660826-A10309A5-FB1A-4250-BDCF-CA851F45CD4AQ42437312-24ACC3D1-B728-43BF-8A6F-E73B68C27FDAQ46369173-1442F22B-F1D2-4993-8AD7-A565956AC88FQ47100454-C548EEBF-8B03-410E-9104-9EB4F9AB5689Q47357292-1F9A85FB-97EB-4816-A69C-508FB6DFA958Q48226529-4A2B8D23-A833-408F-B850-B72AD3C3991BQ48246091-94F26CE3-1370-4F7F-93A0-2C9C109E5132Q50784573-D41D215F-6D89-43A3-BA62-BB9356B39A8AQ51321659-06B2B712-26D4-424A-98C2-CF9AFFD37352Q55091825-C2015C40-EA2A-430F-92F2-3838940792A5
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The challenge of exploiting ABCG2 in the clinic.
@ast
The challenge of exploiting ABCG2 in the clinic.
@en
The challenge of exploiting ABCG2 in the clinic.
@nl
type
label
The challenge of exploiting ABCG2 in the clinic.
@ast
The challenge of exploiting ABCG2 in the clinic.
@en
The challenge of exploiting ABCG2 in the clinic.
@nl
prefLabel
The challenge of exploiting ABCG2 in the clinic.
@ast
The challenge of exploiting ABCG2 in the clinic.
@en
The challenge of exploiting ABCG2 in the clinic.
@nl
P2093
P2860
P1476
The challenge of exploiting ABCG2 in the clinic
@en
P2093
Caterina Ierano
Susan E Bates
Zhirong Zhan
P2860
P304
P356
10.2174/138920111795163913
P50
P577
2011-04-01T00:00:00Z